BeyondSpring Inc.

NASDAQ:BYSI

1.97 (USD) • At close September 6, 2024
Bedrijfsnaam BeyondSpring Inc.
Symbool BYSI
Munteenheid USD
Prijs 1.97
Beurswaarde 79,391,788
Dividendpercentage 0%
52-weken bereik 0.653 - 4
Industrie Biotechnology
Sector Healthcare
CEO Dr. Lan Huang Ph.D.
Website https://www.beyondspringpharma.com

An error occurred while fetching data.

Over BeyondSpring Inc.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell

Vergelijkbare Aandelen

Sera Prognostics, Inc. logo

Sera Prognostics, Inc.

SERA

7.25 USD

ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V.

PRQR

1.855 USD

MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc.

INKT

0.788 USD

Freeline Therapeutics Holdings plc logo

Freeline Therapeutics Holdings plc

FRLN

6.49 USD

BioSig Technologies, Inc. logo

BioSig Technologies, Inc.

BSGM

0.41 USD

Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc.

CRVS

4.03 USD

Syros Pharmaceuticals, Inc. logo

Syros Pharmaceuticals, Inc.

SYRS

1.515 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)